Dataset from A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease

The purpose of this study is to asses the pharmacokinetics and safety of dexlansoprazole modified release (MR), once daily (QD), in adolescent subjects (age 12-17 years old) with Symptomatic Gastroesophageal Reflux Disease.

本研究旨在评估每日一次（once daily, QD）给药的右兰索拉唑修饰释放（modified release, MR）制剂，在12至17岁患有症状性胃食管反流病（Symptomatic Gastroesophageal Reflux Disease）的青少年受试者中的药代动力学与安全性。